Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adalimumab Clear all
Completed Phase 1 Interventional

Open-Label Adalimumab for Ulcerative Colitis Patients

NCT00421642
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 8, 2026, 5:52 PM EDT
Completed No phase listed Observational Results available

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
no intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
34
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 8, 2026, 5:52 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

NCT00731757
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
Humira
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01970475
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 501, Adalimumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Victorville, California • Jupiter, Florida • Sandy Springs, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Sep 8, 2026, 5:52 PM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965
View directory record Official record
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab, methotrexate, placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

NCT00185562
View directory record Official record
Conditions
Osteoarthritis
Interventions
Adalimumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

NCT02019472
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

NCT00525902
View directory record Official record
Conditions
Uveitis
Interventions
Adalimumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, adalimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 8, 2026, 5:52 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

NCT02745080
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Adalimumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
19
States / cities
Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

NCT05909852
View directory record Official record
Conditions
Adalimumab
Interventions
ABP 501-HCF, ABP 501-LCF
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

NCT03210259
View directory record Official record
Conditions
Psoriasis
Interventions
Humira®, BI 695501
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 8, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246
View directory record Official record
Conditions
Sarcoidosis
Interventions
Adalimumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

NCT02437253
View directory record Official record
Conditions
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 8, 2026, 5:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

NCT03153319
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions
Adalimumab Injection [Humira], Saline Solution for Injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

NCT02207244
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 8, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 8, 2026, 5:52 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 8, 2026, 5:52 PM EDT